Ibio Inc (IBIO)

Nov 24, 2025, 4:15 PM EST - 13 days ago

iBio to Participate in the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 4:01 PM EST - 25 days ago

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

Oct 30, 2025, 7:00 AM EDT - 5 weeks ago

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

Oct 23, 2025, 7:00 AM EDT - 6 weeks ago

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 21, 2025, 7:00 AM EDT - 6 weeks ago

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

Sep 5, 2025, 7:30 AM EDT - 3 months ago

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Aug 25, 2025, 7:00 AM EDT - 3 months ago

iBio Announces Closing of $50 Million Public Offering

Aug 19, 2025, 8:01 AM EDT - 3 months ago

iBio Announces Pricing of $50 Million Public Offering

Aug 18, 2025, 4:01 PM EDT - 3 months ago

iBio Announces Proposed Public Offering

Jun 24, 2025, 7:00 AM EDT - 5 months ago

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Jun 23, 2025, 4:15 PM EDT - 5 months ago

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

Jun 16, 2025, 7:00 AM EDT - 6 months ago

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

May 5, 2025, 8:00 AM EDT - 7 months ago

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 2, 2025, 8:00 AM EDT - 7 months ago

iBio Reports Fiscal Third Quarter 2025 Financial Results

Apr 29, 2025, 1:43 PM EDT - 7 months ago

iBio Raises $6.2 Million Through Warrant Inducement Transaction

Apr 22, 2025, 8:00 AM EDT - 8 months ago

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

Apr 7, 2025, 7:00 AM EDT - 8 months ago

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Feb 19, 2025, 4:05 PM EST - 10 months ago

iBio to Begin Trading on the Nasdaq Stock Exchange

Feb 10, 2025, 4:05 PM EST - 10 months ago

iBio Reports Fiscal Second Quarter 2025 Financial Results

Jan 2, 2025, 7:00 AM EST - 1 year ago

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

Nov 12, 2024, 4:05 PM EST - 1 year ago

iBio Reports Fiscal First Quarter 2025 Financial Results

Sep 20, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sep 3, 2024, 7:00 AM EDT - 1 year ago

iBio to Participate in Upcoming Investor Conferences

Aug 12, 2024, 4:30 PM EDT - 1 year ago

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

Jun 3, 2024, 7:00 AM EDT - 1 year ago

iBio Closes Sale of Manufacturing Facility in Texas

May 13, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Mar 27, 2024, 2:43 PM EDT - 1 year ago

iBio stock nearly tripled on Wednesday: here's why

Mar 27, 2024, 7:00 AM EDT - 1 year ago

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Mar 26, 2024, 7:35 PM EDT - 1 year ago

iBio Announces $15.0 Million Private Placement

Feb 26, 2024, 7:45 AM EST - 1 year ago

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Jan 16, 2024, 8:15 AM EST - 2 years ago

iBio Announces Participation in 23rd Annual PepTalk Conference

Jan 16, 2024, 6:50 AM EST - 2 years ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI VYNE

Dec 26, 2023, 7:15 AM EST - 2 years ago

iBio Amends and Extends Maturity of Credit Agreement

Dec 5, 2023, 8:00 AM EST - 2 years ago

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Nov 27, 2023, 5:20 PM EST - 2 years ago

iBio Announces Reverse Stock Split

Nov 1, 2023, 8:24 AM EDT - 2 years ago

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

Oct 2, 2023, 6:45 AM EDT - 2 years ago

iBio Explains Recent Filing of Registration Statement

Sep 27, 2023, 4:19 PM EDT - 2 years ago

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Sep 21, 2023, 4:05 PM EDT - 2 years ago

iBio Announces Amendment to Credit Agreement with Woodforest

Aug 14, 2023, 4:15 PM EDT - 2 years ago

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

Jun 27, 2023, 8:00 AM EDT - 2 years ago

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

Jun 12, 2023, 4:15 PM EDT - 2 years ago

iBio Forges Research Collaboration with the National Institutes of Health

May 9, 2023, 4:30 PM EDT - 2 years ago

iBio to Participate in the JMP Securities Life Sciences Conference

Apr 4, 2023, 4:05 PM EDT - 2 years ago

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

Mar 31, 2023, 8:10 AM EDT - 2 years ago

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

Feb 16, 2023, 4:48 PM EST - 3 years ago

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

Dec 9, 2022, 4:05 PM EST - 3 years ago

iBio Announces Closing of $3.5 Million Underwritten Public Offering

Dec 6, 2022, 11:27 PM EST - 3 years ago

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

Dec 6, 2022, 4:01 PM EST - 3 years ago

iBio Announces Proposed Underwritten Public Offering

Dec 5, 2022, 8:00 AM EST - 3 years ago

iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022